AstraZeneca pluck chief exec from rival Roche

Wednesday 29 August 2012 10:10 BST
Comments

AstraZeneca yesterday poached its new chief executive from Swiss rival Roche in a bid to kick-start the UK drugs giant, which will see many of its top-selling drugs come off patent in the next two years.

The company has also suffered a series of multi-million pound clinical trial failures.

Pascal Soriot, 53, who practised as a vet before moving into the pharmaceutical industry, will join AstraZeneca at the start of October.

He headed the cancer drug group Genentech before its $100m (£63m) takeover by Roche in 2009, where he became head of pharmaceuticals.

Frenchman Mr Soriot replaces David Brennan, who became one of the most high-profile casualties of the shareholder spring. Mr Brennan resigned in April, hours before the firm's annual meeting.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in